{"id":"W3161800158","doi":"10.1016/s1470-2045(21)00090-5","title":"Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Vifor Pharma; European Organisation for Research and Treatment of Cancer; National Cancer Institute; Medac; KWF Kankerbestrijding; Daiichi-Sankyo; Brain Tumour Charity; NRG Oncology; Atara Biotherapeutics; AstraZeneca; American College of Radiology; Novocure; Douglas Pharmaceuticals; Merck Sharp and Dohme; Cancer Australia; National Health and Medical Research Council; Cancer Research UK; Medical Research Council; Celgene","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Interim analysis; Radiation therapy; Glioma; Dacarbazine; Clinical trial; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001193768,0.0003274387,0.002706667,0.0002961492,0.0001520701,0.00005228664,0.000338911,0.00009668279,0.0003877203],"category_scores_gemma":[0.0003385326,0.0002144016,0.0001730656,0.0008082386,0.0001692461,0.00006370294,0.0002980306,0.0002054384,0.000006385866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001716065,"about_ca_system_score_gemma":0.0002805419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001151134,"about_ca_topic_score_gemma":0.002533745,"domain_scores_codex":[0.9972726,0.0005659508,0.0008409418,0.0006461619,0.0002286635,0.0004456732],"domain_scores_gemma":[0.9967959,0.001545216,0.000423723,0.0007642854,0.0002910027,0.0001798796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.171012,0.2477794,0.199167,0.0007960425,0.1060625,0.009113389,0.03136591,0.00009013338,0.1149748,0.0002710115,0.02050168,0.09886617],"study_design_scores_gemma":[0.7809854,0.05631204,0.104726,0.0001155074,0.02502909,0.0002103205,0.01382505,0.005414977,0.008942318,0.00004516533,0.003911961,0.0004821603],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916645,0.0007879042,0.0001053887,0.0009333447,0.000257241,0.005571758,0.0003041694,0.00002509975,0.0003505746],"genre_scores_gemma":[0.9974802,0.00006965391,0.0001422191,0.0003704589,0.0001366728,0.001507073,0.0001958516,0.0000294846,0.00006834996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6099734,"threshold_uncertainty_score":0.8743044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.100699480469896,"score_gpt":0.4439617932321269,"score_spread":0.343262312762231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}